<--GAT-->
Clinical Topics

Some RCC Risk Factors Can Be Modified

by U.S. Medicine

January 1, 2019

SAN ANTONIO—Obesity, hypertension and smoking are the three modifiable risk factors that could aggressively be targeted to reduce renal cell carcinoma, according to a new study.

A study team from the University of Texas Health Science Center and the South Texas Veterans Healthcare System sought to determine what those are to target disease prevention and reduce healthcare costs.

For an analysis in the journal Urologic Oncology, the researchers used data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, looking at the primary outcome of kidney cancer and focusing on demographics and modifiable risk factors.1

PLCO is a large population-based randomized trial designed and sponsored by the National Cancer Institute to determine the effects of screening on cancer-related mortality and secondary endpoints in men and women aged 55 to 74. The screening component of the trial was completed in 2006, with participants followed and additional data collected through 2015. 

After missing data were excluded, the researchers analyzed 149,683 participants, noting that 0.5% developed renal cancer. Significantly associated with renal cancer in bivariate analysis (P<0.05) was age, male gender, body mass index, diabetes and hypertension, according to the study team, which added that men have a significant increased risk of kidney cancer over women (hazard ratio [HR] = 1.85; 95% CI: 1.58-2.16; P<0.0001).

Age was identified as a nonmodifiable risk factors associated with kidney

(HR = 1.05; 95% CI: 1.01; 1.05, P = 0.001). Modifiable risk factors include:

  • Obesity measured by body mass index (HR = 1.05; 95% CI: 1.02-1.07; P<0.0001),
  • Hypertension (HR = 1.32; 95% CI: 1.13-1.54; P = 0.0004), and
  • Smoking in pack-years (HR = 1.04; 95% CI: 1.02-1.07; P = 0.0002).

1. Gelfond J, Al-Bayati O, Kabra A, Iffrig K, Kaushik D, Liss MA. Modifiable risk factors to reduce renal cell carcinoma incidence: Insight from the PLCO trial. Urol Oncol. 2018 Jul;36(7):340.e1-340.e6. doi: 10.1016/j.urolonc.2018.04.011. Epub 2018 May 17. PubMed PMID: 29779672.



Related Articles

HIV Patients Had Lower PC Incidence in VA Study

NEW YORK—Non-AIDS defining cancers are increasingly important contributors to health outcomes for aging persons with HIV (PWH), according to a recent conference presentation which also pointed out that, although prostate cancer is prevalent in aging... View Article

VA Study Finds No Link Between ADT, Dementia

LA JOLLA, CA—Research has been conflicting on whether androgen deprivation therapy is related to dementia. A research letter in JAMA Oncology pointed out that two studies reported a strong statistically significant association between ADT and... View Article


U.S. Medicine Recommends


More From oncology

Oncology

Overcoming Radiation Resistant Prostate Cancer

ATLANTA—The VA has rolled out a number of telehealth initiatives over the last years, with remote visits to dermatologists being offered to more and more veterans. But how well is the program working? A new... View Article

Oncology

JAK Enzymes Can Treat Leukemia, Lymphoma

ATLANTA—The VA has rolled out a number of telehealth initiatives over the last years, with remote visits to dermatologists being offered to more and more veterans. But how well is the program working? A new... View Article

Oncology

Response of Veterans to PD-1 Checkpoint Inhibitors

ATLANTA—The VA has rolled out a number of telehealth initiatives over the last years, with remote visits to dermatologists being offered to more and more veterans. But how well is the program working? A new... View Article

Oncology

Surgical Staging Often Inadequate for Gallbladder Cancer

Guidelines frequently aren’t followed when it comes to radical cholecystectomy with regional lymphadenectomy for patients with T1b gallbladder cancer.

Oncology

Use of Hospice During Treatment Has Limited VA Use

Unlike in most private sector settings, veterans with advanced cancer can receive hospice care concurrently with treatments such as radiation and chemotherapy.

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up